SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The community is focused on the rapid and severe value collapse of the memecoin following its launch, which many traders are characterizing as a blatant rug pull. While some participants express amusement or cynicism toward the speculative nature of the token, others are debating whether the price drop presents a potential entry point for a rebound.

iShares Ethereum Trust (The) - iShares Ethereum Trust ETF

iShares Ethereum Trust ETF

ETHA is trending as investors monitor Ethereum's significant spot volume growth relative to Bitcoin, fueling speculation about a potential price breakout to higher resistance levels. While some traders view the ETF as a core long-term asset for institutional exposure, others debate its liquidity advantages compared to staking-focused alternatives.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is trending as investors debate whether the recent underperformance of mega-cap tech stocks signals a broader market shift or provides a buying opportunity. Discussions highlight sector rotation, valuation concerns relative to semiconductor momentum, and the impact of heavy AI capital expenditures on future earnings growth.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

The community conversation regarding Avalanche is sharply divided between traders viewing current price levels as an undervalued accumulation opportunity and critics citing concerns over inflation, tokenomics, and perceived lack of institutional momentum. While some participants point to real-world adoption and institutional partnerships as long-term catalysts, others express frustration with sustained downward price pressure and the coin's weak performance relative to other major assets.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is receiving significant attention as traders express optimism regarding the project's institutional potential, specifically citing partnerships like Visa Direct and the UAE's ASK Group. While some in the community highlight these developments as major catalysts for long-term growth, others remain skeptical or frustrated by recent price volatility and slow network adoption.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, E-Vapor Products and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The E-Vapor Products segment contracts with third-party importers to supply all of its products and sells its e-vapor products to customers in the United States. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is trending as investors rotate toward defensive, high-dividend assets amid market uncertainty, with many users highlighting the stock's stability and consistent payout as a hedge against volatility. Discussion also focuses on the company's long-term growth potential through nicotine alternatives and strategic positioning in the evolving tobacco landscape.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is facing significant negative sentiment from the community, with many traders criticizing its declining token value and perceived lack of user adoption or demand. While some investors emphasize the potential of technical upgrades like Polkadot 2.0 and stablecoin proposals to provide future utility, the prevailing discussion is dominated by skepticism and bearish sentiment regarding its long-term viability.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing active discussion regarding upcoming Q2 earnings, with investors weighing the company's growth catalysts—such as the IHEEZO retina data, BYOOVIZ launch, and VEVYE prescription trends—against past management guidance misses. While sentiment remains divided, many traders maintain a long-term bullish outlook, focusing on potential institutional accumulation and the company's expanding ophthalmic platform despite recent short-term volatility.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

The KraneShares CSI China Internet ETF is trending as investors monitor potential catalysts including the upcoming U.S.-China summit and shifting trade dynamics. While some traders express ongoing frustration with the asset's historical underperformance compared to U.S. markets, others are actively accumulating positions, citing compelling valuations and expectations for a rebound driven by potential stimulus measures and stabilizing geopolitical relations.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD is experiencing significant downward pressure and high volatility, with traders citing concerns over a potential prolonged recession in China and a lack of market confidence in Chinese equities despite strong quarterly earnings and active share buybacks. Sentiment remains highly polarized, with many retail investors expressing frustration over the stock's repeated price declines while others see a long-term value opportunity at current cash-rich valuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IOVA In short, further validation of the investment thesis. 
 
 1. We can expect, at minimum, the same NSCLC results as those shared back in November, despite the softer lymphodepletion protocol, which should support adoption. We remain on track for a data readout in Q4 2026 and an sBLA submission in H1 2027, approximately six months after enrollment completion. We have former FDA oncology leaders on board, and we are hiring to build the infrastructure needed for the FDA to grant approval. 
 
 2. We can expect QoQ revenue and margin improvements, driven by structural process improvements and strong Amtagvi demand rather than demand timing reasons. 
 
 3. We should see positive news on sarcoma, IOV-COM-202 (the predecessor to TILVANCE-301), and potentially other programs before the end of the year. 
 
 Anything else?

Candace V

Nobody Important

Cow Bells

Groggok

jtHopeful

Fire_Truck

John Doe

TeDeVan

The Icc

Paul Rusnak

Tyson

Howard Davis

Rober

Elvin

Major

Tony C

Gluteshevaa

StockTwits Web

Iovance Biotherapeutics Inc

 In short, further validation of the investment thesis. 
 
 1. We can expect, at minimum, the same NSCLC results as those shared back in November, despite the softer lymphodepletion protocol, which should support adoption. We remain on track for a data readout in Q4 2026 and an sBLA submission in H1 2027, approximately six months after enrollment completion. We have former FDA oncology leaders on board, and we are hiring to build the infrastructure needed for the FDA to grant approval. 
 
 2. We can expect QoQ revenue and margin improvements, driven by structural process improvements and strong Amtagvi demand rather than demand timing reasons. 
 
 3. We should see positive news on sarcoma, IOV-COM-202 (the predecessor to TILVANCE-301), and potentially other programs before the end of the year. 
 
 Anything else?

@Kai_01 yes this one- 

“Finally, we have a number of ISTs. Again, my team is running they are looking at other cancer types. We have some excitement about more to come on non-melanoma skin cancer. That&#39;s one of my backgrounds. Both Merkel cell and cutaneous squamous cell carcinoma. The two most common cancers in human, by the way. We are looking at other indications. And there&#39;ll be much more we will be sending out a number of there&#39;s a lot to talk about. And we&#39;ll do it in different parts over time. But you can imagine our IR team which is here right now will have a lot to work with in the near future.”

I don’t think they fall under the same programs or categories as frontline melanoma, NSCLC, sarcoma, or endometrial cancer which indicates a bigger pipeline

Susqy

StockTwits for iOS

 yes this one- 

“Finally, we have a number of ISTs. Again, my team is running they are looking at other cancer types. We have some excitement about more to come on non-melanoma skin cancer. That's one of my backgrounds. Both Merkel cell and cutaneous squamous cell carcinoma. The two most common cancers in human, by the way. We are looking at other indications. And there'll be much more we will be sending out a number of there's a lot to talk about. And we'll do it in different parts over time. But you can imagine our IR team which is here right now will have a lot to work with in the near future.”

I don’t think they fall under the same programs or categories as frontline melanoma, NSCLC, sarcoma, or endometrial cancer which indicates a bigger pipeline

@Kai_01 
Pretty much exactly what I heard. 
Q3 release of new guidance. 
I’m guessing lung SBLA may be late 2027 based on needing 6 months from last treated/enrolled patient…

 
Pretty much exactly what I heard. 
Q3 release of new guidance. 
I’m guessing lung SBLA may be late 2027 based on needing 6 months from last treated/enrolled patient…

@Kai_01 
That was a big hint that seems most people missed - Gastman basically said more indications on the way… more studies to release that will keep IR busy lol

 
That was a big hint that seems most people missed - Gastman basically said more indications on the way… more studies to release that will keep IR busy lol

Just For Fun

@USMAgrad Not necessarily :) Enrolment is about to be completed and they need 6 months after that, so on track for 27H1! :)

 Not necessarily :) Enrolment is about to be completed and they need 6 months after that, so on track for 27H1! :)

@Kai_01 
They haven’t been on-time or early w anything so I am guardedly optimistic - more bc of unmet need than bc of IOVA cranking along a speedy timeline😵‍💫

Remember, they have six months from the enrollment of the last patient, but they also have to collate the data into a presentable and compelling format for the SBLA… that will take additional time  ￼

 
They haven’t been on-time or early w anything so I am guardedly optimistic - more bc of unmet need than bc of IOVA cranking along a speedy timeline😵‍💫

Remember, they have six months from the enrollment of the last patient, but they also have to collate the data into a presentable and compelling format for the SBLA… that will take additional time  ￼